000915.SHE Shandong Shanda Wit Science and Technology Co Ltd
- Market cap
- CNY 5.02B
- P/E
- 17.7x
- P/B
- 1.97x
- ROE
- 8.2%
- Dividend yield
- 11.67%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000915.SHE undervalued?
Graham number000915.SHE trades 24.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Shanda Wit Science and Technology Co Ltd fundamental analysis
No fundamental analysis for Shandong Shanda Wit Science and Technology Co Ltd yet.
Shandong Shanda Wit Science and Technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Shanda Wit Science and Technology Co Ltd
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, glycyrrhizin zinc granules, compound calcium carbonate, vitamin AD drops, iprastat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company also provides dextran iron granules, oral rehydration salts, montmorillonite powder, azithromycin granules, rifaximin dry suspension,…
Full company profileShandong Shanda Wit Science and Technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Shanda Wit Science and Technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.54B | 1.77B | 1.53B | 1.80B | 1.82B | 2.03B | 2.34B | 2.48B | 2.13B | 2.23B | 1.18B |
| Gross Profit | 931M | 1.19B | 921M | 1.06B | 1.10B | 1.40B | 1.84B | 2.15B | 1.74B | 1.90B | 915M |
| Operating Income | 399M | 528M | 270M | 414M | 613M | 818M | 1.16B | 1.33B | 1.18B | 1.19B | 402M |
| EBITDA | 464M | 572M | 347M | 447M | 630M | 846M | 1.20B | 1.33B | 1.18B | 1.26B | 425M |
| Net Income | 198M | 243M | 130M | 204M | 291M | 380M | 527M | 585M | 516M | 535M | 209M |
| EPS | 0.85 | 1.04 | 0.55 | 0.87 | 1.24 | 1.62 | 2.25 | 2.50 | 2.20 | 2.28 | 0.89 |
| Balance Sheet | |||||||||||
| Total Assets | 2.48B | 2.78B | 2.90B | 3.15B | 3.69B | 3.94B | 4.69B | 5.20B | 4.93B | 5.00B | 3.93B |
| Total Liabilities | 533M | 556M | 559M | 585M | 760M | 536M | 629M | 702M | 518M | 647M | 295M |
| Shareholders' Equity | 1.28B | 1.50B | 1.60B | 1.73B | 1.95B | 2.24B | 2.58B | 2.98B | 2.91B | 2.86B | 2.55B |
| Cash & Short-term Investments | 618M | 707M | 1.01B | 980M | 1.49B | 1.95B | 2.79B | 3.26B | 3.08B | 2.01B | 538M |
| Total Debt | 40.5M | 21.0M | 20.0M | 20.0M | 29.9M | 9.02M | 7.89M | 67.0K | 2.86M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 501M | 426M | 539M | 244M | 736M | 756M | 1.20B | 1.17B | 930M | 1.27B | - |
| Capital Expenditure | 230M | 178M | 131M | 172M | 102M | 120M | 89.7M | 50.6M | 43.6M | 48.3M | 29.9M |
| Free Cash Flow | 271M | 248M | 407M | 71.1M | 634M | 636M | 1.11B | 1.12B | 886M | 1.22B | -452M |
| Ratios | |||||||||||
| ROE | 15.5% | 16.2% | 8.1% | 11.8% | 14.9% | 16.9% | 20.4% | 19.6% | 17.7% | 18.7% | 8.2% |
| ROA | 8.0% | 8.8% | 4.5% | 6.5% | 7.9% | 9.7% | 11.2% | 11.3% | 10.5% | 10.7% | 5.3% |
| Net Profit Margin | 12.8% | 13.8% | 8.5% | 11.3% | 16.0% | 18.8% | 22.5% | 23.6% | 24.2% | 24.0% | 17.7% |
| Debt to Equity | 0.03x | 0.01x | 0.01x | 0.01x | 0.02x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Shanda Wit Science and Technology Co Ltd dividends
- Dividend yield
- 11.67%
- Forward dividend
- 2.50 CNY
- Payout ratio
- 109.5%
- Ex-dividend date
- Jul 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 586M | 2.50 | 109.5% |
| 2024 | CNY 586M | 2.50 | 113.6% |
| 2023 | CNY 691M | 2.95 | 118.0% |
| 2022 | CNY 340M | 1.45 | 64.5% |
| 2021 | CNY 105M | 0.45 | 27.7% |
| 2020 | CNY 70.3M | 0.30 | 24.2% |
| 2019 | CNY 70.3M | 0.30 | 34.4% |
| 2018 | CNY 52.4M | 0.22 | 40.4% |
| 2017 | CNY 28.5M | 0.12 | 11.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on Jun 16, 2017.
Who owns Shandong Shanda Wit Science and Technology Co Ltd
- Insiders 35.26%
- Institutions 7.99%
- Public & others 56.75%
- Shares outstanding 234M
- Free float 160M
Shandong Shanda Wit Science and Technology Co Ltd company profile
- Company name
- Shandong Shanda Wit Science and Technology Co Ltd
- Ticker
- 000915.SHE
- ISIN
- CNE000000Z28
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 12, 1999
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,719
- Fiscal year end
- December
- Address
- Huatai Plaza, No. 17703, Jinan, China, 250061
- Phone
- 86 53 1851 98090
- Website
- sd-wit.com
About Shandong Shanda Wit Science and Technology Co Ltd
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, glycyrrhizin zinc granules, compound calcium carbonate, vitamin AD drops, iprastat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company also provides dextran iron granules, oral rehydration salts, montmorillonite powder, azithromycin granules, rifaximin dry suspension, and dimercaptosuccinic acid capsules. In addition, it offers information products, such as DLP splicing display units, LCD splicing display units, image stitching processors, communication products, and industrial automation control products; and crystal products. The company is also involved in research, development, production, and sales of children's medicines and health products, as well as leasing and property management services. Shandong Wit Dyne Health Co.,Ltd. was founded in 1993 and is based in Jinan, China.
Shandong Shanda Wit Science and Technology Co Ltd management
5- Ms. Jie YangMD & Director · born 1962
- Mr. Li Fu TanFinancial Director · born 1978
- Mr. Shuwang HeDeputy General Manager & Director · born 1972
- Mr. Liming FanSecretary of the Board · born 1986
- Mr. Long Jiang WangDeputy General Manager · born 1969